Schrodinger announced receipt of a milestone payment from Sanofi to mark the advancement into the clinic of an autoimmune therapy discovered as part of a multi-year, multi-target collaboration between the two companies. Under the terms of the collaboration, Schrodinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple stages of drug discovery, from target analysis and lead optimization to identification of a development candidate. The companies are currently advancing programs in oncology and autoimmune disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.